NEUROKIN strengthens its Board of Directors and Scientific Committee

01-Nov-2010 - France

NEUROKIN announced the appointment of Mr. Bernard Reculeau as a new member of the Board of Directors, and the arrival of Mr. Jesús Benavides within the company’s Scientific Committee.

Bernard has over 25 years of experience in leadership positions in the pharmaceutical industry. At Rhone Poulenc since 1984, he served as General Manager of Pharmuka (launch of Lovenox in France), Senior Vice President Worldwide Industrial Operations, Senior Vice President France and Benelux and finally, Senior Vice President and General manager of Rhone-Poulenc Rorer International. Bernard continued his career at Aventis, where he served as Senior Vice President of pharmaceutical operations until 2005. Bernard also has a good knowledge of biotechnology companies, since he led CISBIO from 2006 to late 2009 and is still, since 2005, a member of the Board of Directors of the Canadian company Theratechnologies.

Bernard graduated from the Institut d’Etudes Politiques de Paris (1974) and the Ecole Nationale d’Administration (1977).

Jesus’ scientific expertise is based on nearly 30 years of experience in R&D within the pharmaceutical industry. He headed until 2000, the department of neurobiology of Sanofi-Synthelabo Research Unit. Between 2000 and 2010 he held various management positions in R&D at Aventis and Sanofi-Aventis. He was Vice President and Head of the Neurodegenerative Diseases Research of Aventis before becoming Vice President and Global Head of Research in Neurology. Nowadays, Jesus also teaches translational neurology in France and Spain; he is a Consultant in pharmaceutical R&D for Pharmaceutical companies and Biotech companies in the field of central nervous system.

Jesús holds a Ph.D. in Biochemistry (Molecular Biology center - University of Madrid).

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Lung ultrasound may be a safe substitute for chest X-ray when diagnosing pneumonia in children

Lung ultrasound may be a safe substitute for chest X-ray when diagnosing pneumonia in children

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis

Cell Receptor Recycling Mechanism Discovery opens up New Class of Therapeutic Targets